Integra Lifesciences (IART)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,944 | 67,741 | 180,550 | 169,075 | 133,892 |
| Depreciation Amortization | 146,486 | 129,676 | 125,144 | 126,866 | 143,522 |
| Income taxes - deferred | -20,731 | -11,885 | -4,585 | -2,755 | -64,138 |
| Accounts receivable | 7,398 | 4,593 | -33,905 | 7,265 | 52,105 |
| Other Working Capital | -31,007 | -81,574 | -39,420 | 18,163 | -41,314 |
| Other Operating Activity | 34,180 | 31,404 | 36,685 | -6,187 | -20,235 |
| Operating Cash Flow | $129,382 | $139,955 | $264,469 | $312,427 | $203,832 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 5,503 | -32,694 | 0 | 0 | N/A |
| PPE Investments | -104,418 | -66,865 | -31,198 | -48,019 | -35,233 |
| Net Acquisitions | -277,811 | N/A | -27,549 | -113,442 | N/A |
| Purchase Sale Intangibles | -9,953 | 0 | 0 | N/A | N/A |
| Other Investing Activity | -14,082 | 5,381 | 167 | 18 | -32,840 |
| Investing Cash Flow | $-390,808 | $-94,178 | $-58,580 | $-161,443 | $-68,073 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 486,500 | 165,100 | 40,750 | 25,500 | 746,500 |
| Debt Repayment | -187,131 | -110,600 | -148,550 | -125,500 | -545,248 |
| Common Stock Issued | 6,398 | 4,317 | 5,465 | 6,824 | 49,795 |
| Common Stock Repurchased | -52,471 | -275,000 | -125,000 | 0 | -100,000 |
| Other Financing Activity | -15,433 | -13,742 | -24,618 | -5,050 | -29,422 |
| Financing Cash Flow | $237,863 | $-229,925 | $-251,953 | $-98,226 | $121,625 |
| Exchange Rate Effect | -6,464 | 3,889 | -10,723 | -9,476 | 13,871 |
| Beginning Cash Position | 276,402 | 456,661 | 513,448 | 470,166 | 198,911 |
| End Cash Position | 246,375 | 276,402 | 456,661 | 513,448 | 470,166 |
| Net Cash Flow | $-30,027 | $-180,259 | $-56,787 | $43,282 | $271,255 |
| Free Cash Flow | |||||
| Operating Cash Flow | 129,382 | 139,955 | 264,469 | 312,427 | 203,832 |
| Capital Expenditure | -104,418 | -66,865 | -42,343 | -48,022 | -38,890 |
| Free Cash Flow | 24,964 | 73,090 | 222,126 | 264,405 | 164,942 |